LIUDMILA LOBACH: Open Payments
NPI 1962832808 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,155 in 45 payments from 11 companies in 2025. Trend: 2023 $748 · 2024 $751 · 2025 $1,155
Food & beverage: $1,155
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $254 |
| Vanda Pharmaceuticals Inc. | 7 | $181 |
| Janssen Pharmaceuticals, Inc | 5 | $162 |
| Alkermes, Inc. | 8 | $136 |
| ABBVIE INC. | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 3 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Almatica Pharma LLC | 3 | $64 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| Lundbeck LLC | 1 | $29 |
Products named: FANAPT, INVEGA SUSTENNA, ABILIFY MAINTENA, VRAYLAR, ABILIFY ASIMTUFII, LYBALVI, COBENFY, UZEDY.
Industry payments across PA — which companies pay providers there.
